The Landscape of Clinical Trials for Claudin18.2-Positive Gastric Cancer - PubMed
4 hours ago
- #Claudin18.2
- #Clinical Trials
- #Gastric Cancer
- Gastric cancer remains a significant global health challenge, especially in advanced stages.
- Claudin-18.2 (CLDN18.2) is a promising therapeutic target for gastric cancer due to its role in maintaining gastric mucosal tight junctions.
- A systematic analysis of 143 clinical trials targeting CLDN18.2-positive gastric cancer was conducted.
- Most trials (69.93%) are in early phases (I/I-II), with increasing phase II and III trials showing promising initial data.
- Two phase IV trials investigating zolbetuximab have been initiated.
- Clinical trial activity is concentrated in East Asia, North America, and Europe, with China leading in research efforts.
- Monoclonal antibodies (32.17%), antibody-drug conjugates (26.57%), and CAR-T therapies (23.08%) are the most common drug types being tested.
- Other innovative treatments include bispecific antibodies, BiTEs, AOCs, and CAR-NK cells.
- CLDN18.2 is emerging as a major target in gastric cancer therapy, with rapid advancements in clinical trials and drug development.
- Future data releases may improve treatment strategies and provide new options for gastric cancer patients.